Product
BCD-263
1 clinical trial
1 indication
Indication
MelanomaClinical trial
A Double-Blind, Randomized Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the SkinStatus: Recruiting, Estimated PCD: 2024-09-01